Nucleic Acid Amplification Testing Market Research, 2032
The global nucleic acid amplification testing market size was valued at $4.8 billion in 2022, and is projected to reach $9.1 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032. Nucleic acid amplification testing is a molecular diagnostic technique used for the detection of nucleic acid such as DNA or RNA in samples such as blood, urine or tissue. The method is typically used for the detection of viruses or pathogens in the sample obtained from the patient which assists in diagnosis of specific disease. Naat plays an important role in disease diagnosis and thus helps healthcare providers to decide the treatment regime. This process involves the amplification of a small amount of target nucleic acids which further allows for easy analysis of the sample.
Furthermore, the amplification is mainly carried out through procedures such as polymerase chain reaction or isothermal amplification. This amplification process facilitates the detection of the target genetic material, even in trace amounts, enabling rapid and precise diagnosis. Nucleic acid amplification testing is used for the detection of various diseases including Malaria, HIV, tuberculosis, COVID 19, sexually transmitted diseases and respiratory tract infections.
Market Dynamics
The major nucleic acid amplification testing market trends includes surge in demand for advanced diagnostic techniques, rise in incidences of infectious diseases and surge in prevalence of cancer cases. As infectious diseases are on the rise around the globe, their management has proved to be a challenge for the healthcare sector. According to a survey “National Hospital Ambulatory Medical Care Survey’ in 2020, there were 3.2 million emergency department visits with infectious and parasitic diseases as the primary diagnosis. Such a huge count of infectious diseases increases the demand for efficient diagnosis techniques such as NAAT. This contributes to the growth of the market.
In addition, rising investment for the development of new biotechnological diagnostic techniques is anticipated to boost the market growth during the forecast period. This investment highlights the industry’s commitment to develop advanced diagnosis techniques and improve healthcare outcomes and thus contribute to the nucleic acid amplification testing market share.
Similarly, techniques such as polymerase chain reaction (PCR) are used to detect the presence of infectious diseases such as HIV, hepatitis, and others. In addition, constant innovations related to test technologies, and service designs have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to molecular diagnostics thereby contributing to the nucleic acid amplification testing market share.
Several factors drive the demand for nucleic acid amplification testing industry but limited awareness about advanced diagnostics techniques in underdeveloped and developing countries may hamper the market growth to some extent. In addition, the high cost of the advanced molecular diagnostic techniques makes it inaccessible for the patients in lower income countries. This may act as a restraint to to the growth of nucleic acid amplification testing market size.
On the other hand, a rise in adoption and awareness regarding point of care testing is anticipated to drive the market growth during the nucleic acid amplification testing market forecast period. The point of care testing is contributing to several changes in the healthcare system. POC technologies allow for the management of various diseases and conditions, particularly in settings where healthcare infrastructure and access to quality and timely medical care are limited. POC testing such as corona virus test when used properly have made medical treatments more efficient.
The ongoing global economic recession influences several industries, including biotechnology and pharmaceuticals, which has an impact on the development and demand of diagnostic testing kits. In addition, small and midsized pharmaceutical companies are particularly affected by the economic crisis, which delays capital-raising plans and causes supply chain interruptions that hinder output. Despite these challenges, the market for nucleic acid amplification tests continues to experience moderate revenue growth due to the ongoing need for diagnostic test kits and systems in the healthcare sector.
Segmental Overview
The nucleic acid amplification testing market is segmented on the basis of technology, application, end user, and region. By technology, the market is segmented into polymerase chain reaction (PCR) tests, and isothermal nucleic acid amplification technology (INAAT) test. The INAAT segment is further segmented into loop mediated isothermal amplification (LAMP), transcription mediated amplification (TMA), nucleic acid sequence based amplification (NASBA), helicase dependent amplification (HDA), rolling circle amplification (RCA) and others.
On the basis of application, the market is categorized into infectious disease testing, oncology testing and other. On the basis of end user, the market is divided into hospitals-based laboratories, central, reference and standalone laboratories, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Technology
On the basis of type, the polymerase chain reaction (PCR) segment dominated the global market in 2022 and is anticipated to remain dominant during the forecast period. The growth of the segment is mainly attributed to the increasing applications of PCR technology in disease diagnostics. In addition, key players in the market are offering PCR kits for the detection of various infectious diseases which can offer accurate and faster results. For instance, PerkinElmer offers PerkinElmer New Coronavirus Nucleic Acid Detection Kit for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal, nasopharyngeal, and anterior nasal swab.
By Application
By application, the infections disease testing segment dominated the market in terms of revenue in 2022, which is attributed to the high prevalence of respiratory tract infections and sexually transmitted infections around the globe. Moreover, these infections are on the rise in the developed as well as lower- and middle-income countries, which is increasing the demand for diagnostic tests in these regions, thereby boosting the segment growth.
By End User
On the basis of end user, the central, reference and standalone laboratories segment dominated the market in terms of revenue in 2022. The growth of the segment is attributed to the surge in adoption of polymerase chain reaction technology in central, reference and standalone laboratories. In addition, these laboratories often specialize in specific areas of diagnostics, such as molecular biology, genetics, or infectious diseases. This specialization allows for in-depth knowledge and expertise in the tests they perform.
On the other hand, the hospitals-based laboratories segment is anticipated to be the fastest growing segment during the forecast period. The growth is mainly attributed to the adoption of point of care testing in developed and developing countries. In addition, hospital-based laboratories allow for coordination between diagnostic testing and treatment which can be quickly shared with healthcare providers, leading to more timely and integrated care.
By Region
The nucleic acid amplification testing industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America region dominated the market in terms of revenue in 2022 and is anticipated to be dominant during the forecast period. The growth in this region is mainly attributed to the well-developed healthcare infrastructure in countries such as U.S., and availability of advanced medical facilities for diagnosis and treatment of the various diseases.
Clinical laboratories are the major diagnostic center conducting a variety of tests on patient samples, including blood, urine, and tissue specimens. These labs are equipped with state-of-the-art technology and skilled professionals to perform tests ranging from routine blood counts to complex genetic analyses. This leads to the higher demand for nucleic acid amplification tests in this region and thus propels nucleic acid amplification testing market growth.
In addition, the surge in adoption of point of care testing is also boosting the market growth in North America. The key players in the market are developing new diagnostic kits which can be used at point of care, this is further contributing to market growth. Also, rising awareness among people regarding advanced diagnostic facilities and early diagnosis of diseases leads to the expansion of the market.
On the other hand, Asia-Pacific is anticipated to be the fastest growing segment during the forecast period. This growth is mainly attributed to the huge population base and high prevalence of microbial infections in this region. Developing countries have insufficient sanitation and poor hygiene practices can contribute to the spread of bacterial infections, which increases the demand for diagnostic kits such as nucleic acid amplification testing. In addition, the presence of several major players, such as Abbott Laboratories, Perkin Elmer Inc, F. Hoffmann-La Roche Ltd. And Siemens AG is also contributing to the market growth in this region.
Competition Analysis
Competition analysis and profiles of the major players in the nucleic acid amplification testing market, such as Hologic, Inc., Grifols, S.A., BioMerieux SA, Illumina Inc., Abbott Laboratories, Perkin Elmer Inc, F. Hoffmann-La Roche Ltd., Siemens AG, Eiken Chemical Co., Ltd. And New England Biolabs. Other key players in the market include HymonBio Co.,Ltd, Thermo Fisher Scientific, Qiagen, Cepheid and others. The key players have adopted product approval as the key strategy to remain competitive in the market.
Recent Product Approvals in the Nucleic Acid Amplification Testing Market
- In May 2022, Grifols announced that it has received FDA approval for the Procleix Panther System for use with the following U.S. licensed products Procleix Ultrio Elite Assay, Procleix WNV Assay, Procleix Zika Virus Assay and the Procleix Babesia Assay.
- In June 2022, Grifols announced that its Procleix Plasmodium Assay has obtained the CE mark, the first for an automated nucleic acid test (NAT) system specifically validated for screening blood donors for malaria.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid amplification testing market analysis from 2022 to 2032 to identify the prevailing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the segmentation assists to determine the prevailing nucleic acid amplification testing market opportunity.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global nucleic acid amplification testing market trends, key players, market segments, application areas, and market growth strategies.
Nucleic Acid Amplification Testing Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 9.1 billion |
 Growth Rate | CAGR of 6.6% |
 Forecast period | 2022 - 2032 |
 Report Pages | 272 |
 By End-user |
|
 By Technology |
|
 By Application |
|
 By Region |
|
 Key Market Players | BioMerieux SA, Abbott Laboratories, Hologic, Inc., Perkin Elmer Inc, F. Hoffmann-La Roche Ltd., Illumina Inc., Eiken Chemical Co., Ltd., Grifols, S.A., Siemens AG, New England Biolabs. |
Analyst Review
The global nucleic acid amplification testing market presents several opportunities and challenges. The increasing prevalence of infections such as tuberculosis, HIV, malaria, and others worldwide remains a key driver for the growth of the nucleic acid amplification testing market.
Furthermore, the elevated worldwide prevalence of communicable diseases has increased the demand for various nucleic acid amplification testing technologies as efficient alternatives for effectively managing disease outbreaks. The emergence of the COVID-19 pandemic has particularly underscored the need for rapid and precise testing methods like nucleic acid amplification testing in detecting the SARS-CoV-2 virus. This increased demand for novel technologies plays a significant role in the timely identification and treatment of infectious diseases which contribute to the market growth.
Furthermore, North America dominated the market in terms of revenue in 2022, owing to well-developed healthcare infrastructure and advanced diagnostics facilities in this region. On the other hand, Asia-Pacific is anticipated to witness notable growth during the forecast period owing to rising awareness among the people regarding early diagnosis of diseases and government initiatives for improving healthcare facilities in this region.
The base year is 2022 in nucleic acid amplification testing market.
The forecast period for nucleic acid amplification testing market is 2023 to 2032.
The total market value of nucleic acid amplification testing market is $4.8 billion in 2022.
The market value of nucleic acid amplification testing market in 2032 is $9.1 billion.
Major players that operate in the NAAT market are Hologic, Inc., Grifols, S.A., BioMerieux SA, Illumina Inc., Abbott Laboratories, Perkin Elmer Inc, F. Hoffmann-La Roche Ltd., Siemens AG, Eiken Chemical Co., Ltd. and New England Biolabs.
The polymerase chain reaction (PCR) tests segment is the most influencing segment in the market which is attributed to the significant demand for PCR test kits in the healthcare sector for detection of various infectious diseases.
Key factors driving the growth of the NAAT market includes surge in demand for advanced diagnostic techniques, rise in incidences of infectious diseases, and surge in prevalence of cancer cases.
Asia-Pacific has the highest growth rate in the market with 7.4% CAGR owing to high population base, high incidence of infectious diseases, and high prevalence of cancer in this region.
Loading Table Of Content...
Loading Research Methodology...
